Arachnophobia clinical trials
The registry lists 26 studies for Arachnophobia across 4 countries. 2 are recruiting or about to start. 16 of them are mainly about Arachnophobia (how this is decided). Per ClinicalTrials.gov, last updated 2026-05-18.
Get an email when these change. Save the Arachnophobia studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Phase
- Phase 4
- 2
Who runs them
Ruhr University of Bochum (5) · University of Texas at Austin (4) · Uppsala University (3) · University of California, Los Angeles (2) · Philipps University Marburg (2) · University of Nevada, Reno (1) · Anke Haberkamp (1) · University of Regensburg (1)
What is being tested here
Drugs under test in Arachnophobia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Propranolol | 1 | 0 | 1 |
| Hydrocortisone | 1 | 0 | 1 |
| Mifepristone | 0 | 0 | 1 |
| Oxytocin | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Dec 2026In Vivo Exposure vs. Videochat-Based Vicarious Exposure · Ruhr University of Bochum
Who these studies take
Of the 2 Arachnophobia studies recruiting now, 0 (0%) set no upper age limit and 2 (100%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 2 (100%) | 2 (100%) |
| 30 | 2 (100%) | 2 (100%) |
| 40 | 2 (100%) | 2 (100%) |
| 50 | 1 (50%) | 1 (50%) |
| 65 | 1 (50%) | 1 (50%) |
| 75 | 0 (0%) | 0 (0%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 26 studies, recruiting or not: 65% stop at 75 or younger and 65% at 65; 0% take children; 8% are for women only and 0% for men only; 35% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Arachnophobia studies take
Of 18 interventional studies with no phase under Arachnophobia, half reached primary completion within 13 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Interventional, no phase | 13 mo9–20 · 18 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
Studies
Recruiting first, then most recently updated. Showing 26 of 26. search them.
- The Effects of Propranolol and Hydrocortisone on Military-Relevant Performance OutcomesRecruitingNCT06982183Phase 41 country
- In Vivo Exposure vs. Videochat-Based Vicarious ExposureRecruitingNCT07432945Not applicable1 country
- Telemedicine-Based Virtual Reality Clinic for the Treatment of PhobiasCompletedNCT06302868Not applicable1 country
- The Effect of Time on Generalization of Exposure-based BenefitCompletedNCT06255821Not applicable1 country
- Optimizing Exposure Using Occasional Aversive Imagery in Spider Fearful IndividualsCompletedNCT05424250Not applicable1 country
- Feasibility of an Online Modeled Exposure in Spider Fearful IndividualsCompletedNCT06182709Not applicable1 country
- Gamification in the Treatment of Spider PhobiaCompletedNCT04423783Not applicable1 country
- The Neural Mechanisms of Imaginal ExtinctionCompletedNCT05168592Not applicable1 country
- Neural Mechanisms of Imaginal and in Vivo ExposureCompletedNCT05193383Not applicable1 country
- Generalized Fear Extinction to Untreated Fear Stimuli in Specific Phobias After ExposureCompletedNCT03907345Not applicable1 country
- Bringing Exposure Therapy to Real-Life Context With Augmented RealityTerminatedNCT03649347Not applicable1 country
- Use of Safety Behaviors in Exposure Therapy for ArachnophobiaCompletedNCT04470882Not applicable1 country
- TMS and Exposure TherapyTerminatedNCT04019054Not applicable1 country
- One-session Treatment for Spider FearsCompletedNCT03410264Not applicable1 country
- Efficacy of Targeted Memory Reactivation for Enhancing Exposure TherapyCompletedNCT04663672Not applicable1 country
- tDCS-Augmented Exposure Therapy for Pathological FearCompletedNCT03095482Not applicable1 country
- Spider Phobia Opposite Action Treatment StudyTerminatedNCT02905279Not applicable1 country
- Efficacy of a Gamified Augmented Reality Exposure-based Application in Subjects With Fear of SpidersCompletedNCT04162509Not applicable1 country
- Optimizing Exposure Therapy With Mental RehearsalCompletedNCT03934385Not applicable1 country
- Effects of Stress on Exposure TherapyCompletedNCT03505437Not applicable1 country
- Neural Activations During Imaginal Exposure in Individuals Fearful of SpidersCompletedNCT03969160Not applicable1 country
- The Role of Treatment Expectation in Exposure Training With Spider Fearful ParticipantsCompletedNCT03012035Not applicable1 country
- 3D Video Virtual Reality Exposure Therapy StudyStatus unknownNCT02584387Not applicable1 country
- Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety DisordersCompletedNCT01631682Phase 41 country
- Extinction Generalization in Exposure TherapyCompletedNCT03031002Not applicable
- EMDR in Spider Phobia: Work Mechanisms and Treatment OutcomeCompletedNCT02973919Not applicable